Micheal Scott

created a new article

2 d - Translate

Johnson & Johnson’s Visionary Role in Addressing Unmet Needs in Oncology | #healthcare

Johnson & Johnson’s Visionary Role in Addressing Unmet Needs in Oncology

Bristol Myers Squibb (BMS) has established itself as a trailblazer in the Molecular Glues market, leading innovation in this cutting-edge therapeutic space. Molecular glues are small molecules that facilitate protein-protein interactions, often targeting proteins once considered "und

Comment

created a new article

14 w - Translate

Pain Management Devices: Market Insights, Growth Potential, and Competitive Outlook - 2030 | #healthcare

Pain Management Devices: Market Insights, Growth Potential, and Competitive Outlook - 2030

Pain management devices are designed to alleviate chronic and acute pain in patients suffering from conditions like arthritis, cancer, musculoskeletal disorders, and post-operative pain.

Comment

created a new article

14 w - Translate

Prostate Cancer Pipeline: 12 Upcoming Drugs Offering Hope in mCRPC and Metastatic Prostate Cancer | #healthcare

Prostate Cancer Pipeline: 12 Upcoming Drugs Offering Hope in mCRPC and Metastatic Prostate Cancer

Prostate cancer remains one of the most common cancers affecting men worldwide. With advancements in medical research, new therapies are emerging to address different stages of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sens

Comment

created a new article

14 w - Translate

Triple X Syndrome Market Opportunities: Epidemiology and Growth Forecast to 2032 | #healthcare

Triple X Syndrome Market Opportunities: Epidemiology and Growth Forecast to 2032

The Triple X syndrome market is primarily driven by increasing awareness, better genetic testing, and advanced diagnostic tools.

Comment

created a new article

14 w - Translate

DUPIXENT Adds COPD to Its Portfolio with First Biologic Approval | #healthcare

DUPIXENT Adds COPD to Its Portfolio with First Biologic Approval

DUPIXENT (dupilumab), developed by Sanofi and Regeneron, has added another significant achievement to its portfolio by receiving the first-ever biologic approval for treating Chronic Obstructive Pulmonary Disease (COPD).

Comment

Load more posts

Info

32 posts
Male
16-04-96
Living in United States

Albums

(0)

Friends

(1)

iVebo Admin

Likes

(0)

Groups

(0)

2 d - Translate

Johnson & Johnson’s Visionary Role in Addressing Unmet Needs in Oncology

14 w - Translate

Pain Management Devices: Market Insights, Growth Potential, and Competitive Outlook - 2030

14 w - Translate

Prostate Cancer Pipeline: 12 Upcoming Drugs Offering Hope in mCRPC and Metastatic Prostate Cancer

14 w - Translate

Triple X Syndrome Market Opportunities: Epidemiology and Growth Forecast to 2032

14 w - Translate

DUPIXENT Adds COPD to Its Portfolio with First Biologic Approval

Language